ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 137

Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents

Chelsea DeCoste1, Suzanne Ramsey 2, Adam Huber 3, Bianca Lang 4 and Elizabeth Stringer 2, 1The Hospital for Sick Children, Toronto, Canada, 2IWK Health Centre, Halifax, Canada, 3IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 4Dalhousie University - Halifax, Halifax, Canada

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Biologic agents, decision conflict, DMARDs, juvenile idiopathic arthritis (JIA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) and biologic agents are routinely used in the treatment of JIA and JIA-associated uveitis (JIA-AU). Parents are often fearful, however, of the potential side effects of these medication.  The term decisional conflict (DC) is used to describe a state of uncertainty about a course of action, such as making a decision about treatment. DC can result in verbalized uncertainty, vacillation between choices, delayed decision making, and signs of emotional and physical distress. This study measured and compared the level of DC in parents when making the decision to begin a DMARD or a biologic for the first time.

Methods: Parents of children with JIA or JIA-AU, whose pediatric rheumatologist recommended beginning a DMARD or biologic for the first time, were invited to participate in this prospective study. The level of DC was measured within one month of enrolment using the Decision Conflict Scale (DCS). The DCS, which has a total of 16 questions across 5 subscales (informed, values clarity, support, uncertainty and effective decision subscales), generates a score from 0-100 with higher scores reflecting greater conflict. Scores ≥ 25 are associated with clinically significant conflict while scores ≥ 37.5 can be associated with decision delay. Parents were asked to indicate their decision on starting the recommended medication for their child. They were also asked to describe factors which affected their decision via an open-ended question. Stata 11 was used for the descriptive analysis.

Results: Forty parents with a mean age of 40.4 ± 6.7 were included in our study; 35 (87.5%) females and 5 (12.5%) males. The mean age of the patients was 10.4 ± 4.5; 25 (62.5%) females and 15 (37.5%) males. The majority of patients were being counselled to begin a DMARD or biologic due to JIA alone (90%), 3 patients (7.5%) for JIA-AU, and 1 for both (2.5%). The mean active joint count was 6.4 ± 7.5. Almost all parents (38/40) indicated that they decided to start the recommended medication; two parents were undecided. The overall mean DC score was 17.3 ± 16.2 (median 10.9, range 0-51). Mean DCS score was 16.1 ± 15 (median 9.4, range 0-50) and 18.8 ± 17.8 (median 14.06, range 0-51) for the DMARD and biologic groups respectively. There was no statistically significant difference between the two groups. The total number of DCS scores ≥ 25, indicating clinically significant conflict, was 14 (37.5%) in both groups, 8 (33.3%) in the DMARD group, and 7 (36.8%) in the biologic group (Figures 1 and 2). Two parents (10%) in the DMARD group and 4 parents (21%) in the biologic group had DCS scores ≥37.5. The 2 undecided parents both had DCS scores < 25.  Factors which contributed to parents making a decision included witnessing ongoing pain in their child, trust in physicians, and previous treatment failures.

Conclusion: Parents of patients with JIA or JIA-AU experienced generally low levels of DC when making the decision to begin DMARDs and biologics for the first time. Still, a third of parents demonstrated clinically significant DC, although this did not lead to a decision delay in our population. The impact of DC on parents deserves further exploration.

Figure 1. Decisional Conflict Scale Score for those being recommended DMARD treatment.

Figure 2. Decisional Conflict Scale Score for those being recommended biologic treatment.


Disclosure: C. DeCoste, None; S. Ramsey, None; A. Huber, None; B. Lang, None; E. Stringer, None.

To cite this abstract in AMA style:

DeCoste C, Ramsey S, Huber A, Lang B, Stringer E. Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/measuring-decision-conflict-in-parents-of-children-with-juvenile-idiopathic-arthritis-when-making-the-decision-to-begin-disease-modifying-anti-rheumatic-drugs-or-biologic-agents/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/measuring-decision-conflict-in-parents-of-children-with-juvenile-idiopathic-arthritis-when-making-the-decision-to-begin-disease-modifying-anti-rheumatic-drugs-or-biologic-agents/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology